AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27865117
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intraaortic balloon pump therapy)
Trial: 27222510
Drug: Insulin glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin glulisine
Trial: 8485067
Drug: Nicorandil 20
RxNorm normalized name: nicorandil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 20 mg bid
Trial: 15618027
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg bid
Trial: 15618027
Drug: Losartan 25
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 25 mg bid
Trial: 8590781
Drug: Structured teaching/treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured teaching/treatment programme
Trial: 28947022
Drug: FF/UMEC (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC (all doses)
Trial: 20057195
Drug: Combined DAK
RxNorm normalized name: Di-Dak-Sol
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DAK therapy for obesity (inpatient therapy for 6 weeks followed by home-based outpatient treatment for 10.5 months)
Trial: 20057195
Drug: Combined DAK
RxNorm normalized name: Di-Dak-Sol
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DAK therapy for obesity
Trial: 17413047
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg daily for up to 14 days)
Trial: 12845405
Drug: METH (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: METH (10 mg)
Trial: 8875970
Drug: HMG-CoA reductase
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitors
Trial: 8445848
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 4.97 +/- 1.12 mg/kg (total dosage per exacerbation: 74.55 mg/kg)
Trial: 8445848
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily aminoglycosides (tobramycin or netilmicin) - total daily dosage: 9.60 +/- 2.70 mg/kg (total dosage per exacerbation: 165.12 mg/kg)
Trial: 29336896
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with 0.3 mg ranibizumab and TRP
Trial: 29336896
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 0.3 mg ranibizumab
Trial: 10753434
Drug: Various medical
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various medical treatments (central vasodilators, vestibular suppressants, calcium channel blockers, anticholinergic drugs, anticonvulsant drugs, gingko biloba)
Trial: 25881589
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment for 10 days followed by esomeprazole 20 mg bid for 46 days
Trial: 25881589
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg bid therapy for 8 weeks (control group)
Trial: 9560861
Drug: Collaborative Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care (enhanced management of pharmacotherapy and brief psychoeducational interventions)
Trial: 8175505
Drug: Dipyridamole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.5 mg/kg)
Trial: 29496472
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg once per day
Trial: 20171409
Drug: Active patch
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active patch containing 10% methyl salicylate and 3% l-menthol
Trial: 17384176
Drug: Low-dose deflazacort
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose deflazacort (DFZ) 7.5 mg for 6 months, followed by methyl prednisolone (MP) 4 mg for 6 months.
Trial: 17384176
Drug: Methyl prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl prednisolone (MP) 4 mg for 6 months, followed by low-dose deflazacort (DFZ) 7.5 mg for 6 months.
Trial: 14971531
Drug: Tramadol SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol SR 100 mg
Trial: 202141
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg)
Trial: 1634645
Drug: Chlorthalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (50 mg)
Trial: 11736880
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg)
Trial: 1634645
Drug: Atenolol and
RxNorm normalized name: atenolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol and Chlorthalidone combination (100 mg and 50 mg)
Trial: 31204832
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy modified for stalking offenders (DBT-S)
Trial: 27861708
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 100,000 IU monthly
Trial: 27861708
Drug: Standard-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose vitamin D (placebo or 12,000 IU)
Trial: 20166442
Drug: Single-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rosuvastatin 5 mg
Trial: 20166442
Drug: Single-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rosuvastatin 10 mg
Trial: 20166442
Drug: Single-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose rosuvastatin 20 mg
Trial: 20166442
Drug: Multiple-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose rosuvastatin 5 mg
Trial: 20166442
Drug: Multiple-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose rosuvastatin 10 mg
Trial: 20166442
Drug: Multiple-dose rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose rosuvastatin 20 mg
Trial: 15598476
Drug: Fluvastatin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin + Fenofibrate combination therapy
Trial: 9223543
Drug: Intrathecal neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal neostigmine + Intravenous alfentanil
Trial: 16321619
Drug: Intravenous alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanil
Trial: 7516376
Drug: Terazosin, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin, dosage not specified, administered once daily.
Trial: 7516376
Drug: Terazosin, long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin, long-term treatment for more than two years.
Trial: 3953352
Drug: Intravenous lorcainide
RxNorm normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lorcainide (2 mg/kg bolus at 2 mg/min followed by 0.14 mg/min or 200 mg/24 hours)
Trial: 3953352
Drug: Oral lorcainide
RxNorm normalized name: tocainide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lorcainide (100 mg orally every 8 hours)
Trial: 30182192
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy (BAT) using the first-generation BAT device
Trial: 30182192
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy (BAT) using the Barostim Neo system
Trial: 26381036
Drug: Intra-abdominal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-abdominal lavage with gentamicin-clindamycin solution (Group 2)
Trial: 19769631
Drug: Medium-dose UVA1
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose UVA1
Trial: 9656312
Drug: Physioacoustic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physioacoustic treatment group
Trial: 2667779
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo and halothane by inhalation
Trial: 2667779
Drug: Nalbuphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.1 mg.kg‐1 IV as premedication and isoflurane by inhalation
Trial: 6608052
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (coronary bypass surgery)
Trial: 29080265
Drug: Autologous cord
RxNorm normalized name: Autologous cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous cord blood (ACB) infusion
Trial: 26044471
Drug: Scheimpflug noncontact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheimpflug noncontact tonometry with daily disposable hydrogel contact lenses (Dailies-nelfilcon A)
Trial: 11097131
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) infusion (mean dose 2.4 +/- 0.9 mg/h), n = 33
Trial: 26671958
Drug: Ebola vaccine
RxNorm normalized name: ebola vaccines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebola vaccine efficacy trial starting after 1 August
Trial: 10743981
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin 70/30
Trial: 14624083
Drug: Active intervention
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intervention (frequent active cervical rotation, assessment and treatment according to McKenzie's principles)
Trial: 10844834
Drug: Rocuronium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium infusion
Trial: 29378515
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control (BAT) - combination of educational classes, sham cognitive training, and balanced and tone exercises
Trial: 25784665
Drug: GLP-1 (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 (1.2 pmol/kg/min) during hyperglycemia (∼12 mmol/L)
Trial: 31045821
Drug: Propofol total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol total intravenous anesthesia (TIVA)
Trial: 18254806
Drug: Folic acid-
RxNorm normalized name: Folic acid-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid- and creatine-containing formulation
Trial: 14751338
Drug: Mepartricin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepartricin (40 mg daily)
Trial: 9555600
Drug: Triazolam (0.1875,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.1875, 0.375, and 0.5625 mg)
Trial: 7912819
Drug: Amisulpride (AMI)
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amisulpride (AMI) 50 mg for 2 weeks, then 100 mg for 4 weeks
Trial: 21719636
Drug: Traditional infant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional infant physical therapy (TIP)
Trial: 16395750
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone with rapid tapering (medrol dose-pack)
Trial: 16395750
Drug: Triamcinolone 100
RxNorm normalized name: TRIAMCINOLONE 100MCG 240D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone 100 mg, given intramuscularly
Trial: 15684846
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment consisting of aromatherapy, footsoak, and reflexology
Trial: 9414079
Drug: Carbohydrate meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate meal three hours before exercise and a carbohydrate‐electrolyte solution during exercise (M + C)
Trial: 9414079
Drug: Carbohydrate‐electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate‐electrolyte solution during exercise (P + C)
Trial: 8119423
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of betamethasone (Betnesol, Glaxo)
Trial: 3311690
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of famotidine
Trial: 17088002
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic tablets
Trial: 8606262
Drug: Placebo (heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (heparin and aspirin only)
Trial: 25403522
Drug: Standard constipation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard constipation treatment options
Trial: 26830074
Drug: Oral agents
RxNorm normalized name: DENTAL AND ORAL AGENTS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral agents
Trial: 10617985
Drug: Algae-produced high-DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algae-produced high-DHA triacylglycerol (170-260 mg/d)
Trial: 7759034
Drug: hydroxyethylsalicyclate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyethylsalicyclate gel
Trial: 2182448
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral verapamil treatment
Trial: 11694805
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (50 microg)
Trial: 11422131
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 800 microg/daily for 6 months
Trial: 2566338
Drug: U.S. manufactured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U.S. manufactured 50 mg film coated, waxed tablets
Trial: 2566338
Drug: European 50
RxNorm normalized name: European blueberry
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: European 50 mg film coated, waxed tablets
Trial: 2566338
Drug: Oral reference
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral reference solution of almitrine bismesylate (0.5% w/v)
Trial: 2566338
Drug: U.S. manufactured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U.S. manufactured tablets vs. European tablets
Trial: 15167852
Drug: Topical bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bupivacaine
Trial: 7717643
Drug: Intramuscular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketorolac
Trial: 1907675
Drug: 45% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45% BCAA solution
Trial: 8471652
Drug: Standard AA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard AA solution (control group)
Trial: 26458517
Drug: Interfering force
RxNorm normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interfering force field B (treatment group)
Trial: 9040722
Drug: Cabergoline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.25 to 4 mg/d)
Trial: 9040722
Drug: Levodopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (100 to 600 mg/d)
Trial: 7955181
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (8 g/d of omega-3 fatty acids, 10 capsules of 1.0 g each containing 80.6% ethyl esters of omega-3 fatty acids, providing 4.1 g EPA and 2.8 g DHA)
Trial: 2962799
Drug: Thymopentin (TP5)
RxNorm normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymopentin (TP5) 50 mg administered subcutaneously 3 times weekly for 1 month
Trial: 11805451
Drug: Topical heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical heat application before exercise in normal controls
Trial: 11805451
Drug: Topical heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical heat application after exercise in normal controls
Trial: 8156047
Drug: Fentanyl 0.250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.250 mg/ml
Trial: 8156047
Drug: Sufentanil 0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.050 mg/ml
Trial: 31934793
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (LDG) - two Iyengar yoga sessions a week
Trial: 31934793
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (HDG) - three Iyengar yoga sessions a week
Trial: 28138765
Drug: Carperitide (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carperitide (0.01 µg/kg/min)
Trial: 23278590
Drug: Eltrombopag 50
RxNorm normalized name: eltrombopag 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 50 mg daily for up to 6 weeks (1 cycle) followed by up to 4 weeks off therapy
Trial: 20844233
Drug: Eltrombopag treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag treatment
Trial: 22047926
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus fentanyl (1 mL of 50 μg)
Trial: 22047926
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus tramadol (1 mL of 50 mg)
Trial: 22047926
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (30 mL of 0.25%)
Trial: 15790189
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg per day for 2 years)
Trial: 9168368
Drug: Hydration solution
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration solution (5% dextrose)
Trial: 3301915
Drug: Listerine antiseptic
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Listerine antiseptic (LA) 2 or 4 times daily for 2 weeks
Trial: 25771388
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (docosahexaenoic acid and eicosapentaenoic acid, 450‐1300 mg/day)
Trial: 21060282
Drug: L-dopa/benserazide (L/B)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/benserazide (L/B)
Trial: 21060282
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (both PPX and L/B)
Trial: 7895551
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole once daily
Trial: 22122999
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lansoprazole once daily
Trial: 1306600
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of placebo with two 50 mg ketoprofen capsules
Trial: 1752851
Drug: Intramuscular route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular route of administration
Trial: 18626633
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) propiverine (10, 15, 30 mg)
Trial: 18626633
Drug: Oral propiverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral propiverine solution (15 mg)
Trial: 10870872
Drug: Zaleplon 20
RxNorm normalized name: Zaleplon
DrugBank: Zaleplon (DB00962)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zaleplon 20 mg
Trial: 11851645
Drug: Zopiclone 7.5
RxNorm normalized name: zopiclone 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone 7.5 mg (active control)
Trial: 7536481
Drug: Aprotinin (250,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (250,000 KIU added to cardiopulmonary bypass prime solution and 250,000 KIU infused intravenously over 30 minutes before bypass)
Trial: 1911011
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen with 5% carbon dioxide
Trial: 1911011
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction of anaesthesia with isoflurane and nitrous oxide in oxygen without 5% carbon dioxide
Trial: 15814512
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion
Trial: 29514333
Drug: Infusion-end plasma
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion-end plasma morphine concentrations
Trial: 29777633
Drug: Daily terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily terbutaline (8 × 0.5 mg) with habitual training